During 1979-1995, there was no vaccination against pertussis in Sweden. With the aim of studying the epidemiology and transmission of pertussis, mass vaccination with pertussis toxoid of children born during the 1990s was instituted in the Göteborg area (population, 778,597) in 1995. Infants were offered 3 doses of pertussis toxoid combined with diphtheria and tetanus toxoids. Children aged > or =1 year were offered 3 doses of pertussis toxoid alone. From June 1995 through February 1999, 167,810 doses of pertussis toxoid were given to 61,219 children born during the 1990s (56% received 3 doses). The number of Bordetella pertussis isolates per year declined from 1214 (1993-1995) to 64 (January 1997 through June 1999; P<.0001), and hospitalizations due to pertussis declined from 62 to 5 (P<.0001). Significant decreases in B. pertussis isolates and hospitalizations occurred in all age groups, including adults and nonvaccinated infants. Thus, mass vaccination of children with pertussis toxoid decreases spread of B. pertussis in the population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1086/322639 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Determination of DTaP vaccine potency by multiplex immunogenicity testing using electrochemiluminescence.
NPJ Vaccines
August 2024
Paul-Ehrlich Institut, Federal Institute for Vaccines and Biomedicines, Paul-Ehrlich-Strasse 51-59, D-63225, Langen, Germany.
Article Synopsis
- The study explores a new method for testing the potency of diphtheria, tetanus, and acellular pertussis (DTaP) vaccines, shifting from traditional in vivo animal testing to simultaneous serological testing on guinea pigs.
- It used established WHO International Standards as references and developed a quantification technique for detecting IgG levels against the vaccine antigens through an advanced immunoassay.
- The results demonstrated the effectiveness of this serological approach in identifying vaccine potency and safety, paving the way for its routine application in place of in vivo animal tests, aligning with ethical considerations pertinent to the 3Rs principle (Replace, Reduce, Refine).
Immunization with an mRNA DTP vaccine protects against pertussis in rats.
Infect Immun
August 2024
Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, West Virginia, USA.
is a Gram-negative bacterium that is the causative agent of the respiratory disease known as pertussis. Since the switch to the acellular vaccines of DTaP and Tap, pertussis cases in the US have risen and cyclically fallen. We have observed that mRNA pertussis vaccines are immunogenic and protective in mice.
View Article and Find Full Text PDFBECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models.
Infect Immun
March 2024
Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, West Virginia, USA.
The protection afforded by acellular pertussis vaccines wanes over time, and there is a need to develop improved vaccine formulations. Options to improve the vaccines involve the utilization of different adjuvants and administration via different routes. While intramuscular (IM) vaccination provides a robust systemic immune response, intranasal (IN) vaccination theoretically induces a localized immune response within the nasal cavity.
View Article and Find Full Text PDFComparative Evaluation of Recombinant and Acellular Pertussis Vaccines in a Murine Model.
Vaccines (Basel)
January 2024
The Vaccine Bio Research Institute, Annex to Seoul Saint Mary Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Since the 2000s, sporadic outbreaks of whooping cough have been reported in advanced countries, where the acellular pertussis vaccination rate is relatively high, and in developing countries. Small-scale whooping cough has also continued in many countries, due in part to the waning of immune protection after childhood vaccination, necessitating the development of an improved pertussis vaccine and vaccination program. Currently, two different production platforms are being actively pursued in Korea; one is based on the aP (acellular pertussis) vaccine purified from containing pertussis toxoid (PT), filamentous hemagglutin (FHA) and pertactin (PRN), and the other is based on the recombinant aP (raP), containing genetically detoxified pertussis toxin ADP-ribosyltransferase subunit 1 (PtxS1), FHA, and PRN domain, expressed and purified from recombinant .
View Article and Find Full Text PDFSafety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
Vaccine
November 2023
Serum Institute of India Private Limited, Pune, India.
Background: This study assessed the safety and immunogenicity of a new booster vaccine against tetanus, diphtheria, and pertussis manufactured by Serum Institute of India Pvt. Ltd (SIIPL Tdap).
Methods: The Phase II/III trial was randomized (2:1), observer blinded and active controlled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!